549 related articles for article (PubMed ID: 37480104)
21. An immune landscape based prognostic signature predicts the immune status and immunotherapeutic responses of patients with colorectal cancer.
Li M; Li W; Yang X; Wang H; Peng Y; Yin J; Lu Y; Liu L; Shang J; Zhao Q
Life Sci; 2020 Nov; 261():118368. PubMed ID: 32888940
[TBL] [Abstract][Full Text] [Related]
22. Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies.
Zhang Y; Xu J; Zhang N; Chen M; Wang H; Zhu D
Cancer Lett; 2019 Aug; 458():123-135. PubMed ID: 31121212
[TBL] [Abstract][Full Text] [Related]
23. Significant association of MCP1 rs1024611 and CCR2 rs1799864 polymorphisms with colorectal cancer and liver metastases susceptibility and aggressiveness: A case-control study.
Boughriba R; Sahraoui G; Chaar I; Weslati M; Ayed K; Ounissi D; Hazgui M; Bouraoui S; Gati A
Cytokine; 2023 Jul; 167():156193. PubMed ID: 37149962
[TBL] [Abstract][Full Text] [Related]
24. Captopril, a Renin-Angiotensin System Inhibitor, Attenuates Tumour Progression in the Regenerating Liver Following Partial Hepatectomy.
Riddiough GE; Walsh KA; Fifis T; Kastrappis G; Tran BM; Vincan E; Muralidharan V; Christophi C; Gordon CL; Perini MV
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563674
[TBL] [Abstract][Full Text] [Related]
25. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.
Chen Y; Zheng X; Wu C
Front Immunol; 2021; 12():792691. PubMed ID: 34925375
[TBL] [Abstract][Full Text] [Related]
26. The relationship between primary colorectal cancer histology and the histopathological growth patterns of corresponding liver metastases.
Höppener DJ; Stook JPL; Galjart B; Nierop PMH; Nagtegaal ID; Vermeulen PB; Grünhagen DJ; Verhoef C; Doukas M;
BMC Cancer; 2022 Aug; 22(1):911. PubMed ID: 35996090
[TBL] [Abstract][Full Text] [Related]
27. Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery.
Long L; Xiong W; Lin F; Hou J; Chen G; Peng T; He Y; Wang R; Xu Q; Huang Y
J Exp Clin Cancer Res; 2023 May; 42(1):117. PubMed ID: 37161591
[TBL] [Abstract][Full Text] [Related]
28. Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress.
Bahrami A; Khazaei M; Hassanian SM; ShahidSales S; Joudi-Mashhad M; Maftouh M; Jazayeri MH; Parizade MR; Ferns GA; Avan A
J Cell Physiol; 2018 Apr; 233(4):2928-2936. PubMed ID: 28574572
[TBL] [Abstract][Full Text] [Related]
29. MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.
Li X; Nie J; Mei Q; Han WD
World J Gastroenterol; 2016 Jun; 22(23):5317-31. PubMed ID: 27340348
[TBL] [Abstract][Full Text] [Related]
30. Immunological Assessment of Recent Immunotherapy for Colorectal Cancer.
Das S; Acharya D
Immunol Invest; 2023 Nov; 52(8):1065-1095. PubMed ID: 37812224
[TBL] [Abstract][Full Text] [Related]
31. Molecular Mechanisms of Colorectal Liver Metastases.
Tsilimigras DI; Ntanasis-Stathopoulos I; Pawlik TM
Cells; 2023 Jun; 12(12):. PubMed ID: 37371127
[TBL] [Abstract][Full Text] [Related]
32. Emerging mechanisms progress of colorectal cancer liver metastasis.
Zhao W; Dai S; Yue L; Xu F; Gu J; Dai X; Qian X
Front Endocrinol (Lausanne); 2022; 13():1081585. PubMed ID: 36568117
[TBL] [Abstract][Full Text] [Related]
33. Single-cell transcriptome analysis reveals tumor immune microenvironment heterogenicity and granulocytes enrichment in colorectal cancer liver metastases.
Zhang Y; Song J; Zhao Z; Yang M; Chen M; Liu C; Ji J; Zhu D
Cancer Lett; 2020 Feb; 470():84-94. PubMed ID: 31610266
[TBL] [Abstract][Full Text] [Related]
34. The progress of non-alcoholic fatty liver disease as the risk of liver metastasis in colorectal cancer.
Lv Y; Patel N; Zhang HJ
Expert Rev Gastroenterol Hepatol; 2019 Dec; 13(12):1169-1180. PubMed ID: 31774328
[No Abstract] [Full Text] [Related]
35. Immunotherapy for colorectal cancer: where are we heading?
Basile D; Garattini SK; Bonotto M; Ongaro E; Casagrande M; Cattaneo M; Fanotto V; De Carlo E; Loupakis F; Urbano F; Negri FV; Pella N; Russano M; Brunetti O; Scartozzi M; Santini D; Silvestris N; Casadei Gardini A; Puzzoni M; Calvetti L; Cardarelli N; Aprile G
Expert Opin Biol Ther; 2017 Jun; 17(6):709-721. PubMed ID: 28375039
[TBL] [Abstract][Full Text] [Related]
36. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting.
Aristin Revilla S; Kranenburg O; Coffer PJ
Front Immunol; 2022; 13():903564. PubMed ID: 35874729
[TBL] [Abstract][Full Text] [Related]
37. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X
Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive genomic analysis contrasting primary colorectal cancer and matched liver metastases.
Shiomi A; Kusuhara M; Sugino T; Sugiura T; Ohshima K; Nagashima T; Urakami K; Serizawa M; Saya H; Yamaguchi K
Oncol Lett; 2021 Jun; 21(6):466. PubMed ID: 33907576
[TBL] [Abstract][Full Text] [Related]
39. GPR37 promotes colorectal cancer liver metastases by enhancing the glycolysis and histone lactylation via Hippo pathway.
Zhou J; Xu W; Wu Y; Wang M; Zhang N; Wang L; Feng Y; Zhang T; Wang L; Mao A
Oncogene; 2023 Nov; 42(45):3319-3330. PubMed ID: 37749229
[TBL] [Abstract][Full Text] [Related]
40. Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer.
Voß H; Wurlitzer M; Smit DJ; Ewald F; Alawi M; Spohn M; Indenbirken D; Omidi M; David K; Juhl H; Simon R; Sauter G; Fischer L; Izbicki JR; Molloy MP; Nashan B; Schlüter H; Jücker M
Clin Exp Metastasis; 2020 Dec; 37(6):649-656. PubMed ID: 33099724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
